Clinical Trials Logo

Biliary Tract Neoplasms clinical trials

View clinical trials related to Biliary Tract Neoplasms.

Filter by:

NCT ID: NCT06467357 Not yet recruiting - Clinical trials for Biliary Tract Cancer

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

DESTINY-BTC01
Start date: June 26, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.

NCT ID: NCT06465563 Not yet recruiting - Clinical trials for Biliary Tract Cancer

Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer

Start date: July 1, 2024
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the efficacy and safety of SHR-8068 and Adebrelimab in Combination With Cisplatin Plus Gemcitabine(CisGem), compared with Adebrelimab in Combination With CisGem, as first-line treatment in patients with Advanced Biliary Tract cancer.

NCT ID: NCT06451497 Recruiting - Prostate Cancer Clinical Trials

Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Start date: May 22, 2024
Phase: Phase 1
Study type: Interventional

This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Pembrolizumab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.

NCT ID: NCT06431490 Not yet recruiting - Clinical trials for Biliary Tract Cancer

A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer

Start date: July 2024
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the efficacy and safety TQB2102 for injection in the treatment of patients with Her2-positive biliary tract cancer.

NCT ID: NCT06428409 Not yet recruiting - Colorectal Cancer Clinical Trials

A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A)

Start date: June 19, 2024
Phase: Phase 2
Study type: Interventional

Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with chemotherapy can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn: - About the safety and how well people tolerate sacituzumab tirumotecan lone or with chemotherapy - How many people have the cancer respond (get smaller or go away) to treatment

NCT ID: NCT06413745 Not yet recruiting - Clinical trials for HER2 Expression / Amplification in Patients With Biliary Tract Cancer

Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

Start date: May 2024
Phase: Phase 2
Study type: Interventional

This study was to evaluate the efficacy and safety of SHR-A1811 in patients with locally advanced unresectable or recurrent metastatic BTC with HER2 expression / amplification who failed first-line or second-line systemic treatment.

NCT ID: NCT06397430 Completed - Postoperative Clinical Trials

Nutritional Support for Patients Operated for Malignant Tumors in HPD Zone

Start date: December 1, 2017
Phase: N/A
Study type: Interventional

A comprehensive comparative analysis of the effectiveness of isolated enteral, isolated parenteral and mixed type of nutritional support in the early postoperative period in patients after operations performed on the malignant neoplasms of hepatico-pancreatico-duodenal zone.

NCT ID: NCT06389500 Not yet recruiting - Clinical trials for Biliary Tract Cancer

HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

This is a single-arm, exploratory, phase II trial to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy combined with adebrelimab and lenvatinib for borderline resectable, locally advanced biliary tract cancer.

NCT ID: NCT06375967 Not yet recruiting - Clinical trials for Biliary Tract Neoplasms

EUS-Gallbladder vs CDS as First Line in MBDO- Palliative (CARPEGIEM Trial)

CARPEGIEM
Start date: June 2024
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate technical, clinical and safety outcomes of lumen-apposing metal stent (LAMS) with a coaxial double-pigtail plastic stent (DPS) in EUS-guided choledochoduodenostomies vs cholcystogastrostomy for the management of malignant biliary obstruction in palliative patients.

NCT ID: NCT06375954 Not yet recruiting - Pancreatic Cancer Clinical Trials

EUS-guided CDS vs ERCP as First Line in Malignant Distal Obstruction in Borderline Disease (CARPEDIEM-2 Trial)

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The aim of this clinical trial is to evaluate temporal delay (days) between biliary drainage (EUS-CDS vs ERCP as first line therapy) and chemotherapy start in patients with borderline distal malignant biliary obstruction.